• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 19.1BBs vs. placebo for Cardiac Syndrome X

Quality assessmentSummary of findings
No of patientsEffectQuality
No of studiesDesignLimitationsInconsistencyIndirectnessImprecisionOther considerationsBBcontrolRelative (95% CI)Absolute
ischemic episodes - propanolol vs. placebo (follow-up 7 days; range of scores: -; better indicated by less)
Bugiardini 1989229(c)randomised trial (b)serious (a)no serious inconsistencyno serious indirectnessno serious imprecisionnone1616-MD3.2 lower (4.13 to 2.27 lower)[plus sign in circle][plus sign in circle]○○

LOW
ischemic duration (min) - propanolol vs. placebo (follow-up 7 days; range of scores: -; better indicated by less)
Bugiardini 1989229randomised trial (b)serious (a)no serious inconsistencyno serious indirectnessno serious imprecisionnone1616-MD 25 lower (34.15 to 15.85 lower)[plus sign in circle][plus sign in circle]○○

LOW
a

Bugiardini 1989[223]: Randomisation and allocation concealment unclear, small sample size

b

Crossover design

c

Propanolol 120–160mg daily (optimal dose for each patient determined 2–3 weeks before the double blind study ; beta blockade occurred at 120mg a day in 6 patients and at 160mg in 10)

Bugiardini 1989[223]: Randomisation and allocation concealment unclear, small sample size

Crossover design

Propanolol 120–160mg daily (optimal dose for each patient determined 2–3 weeks before the double blind study ; beta blockade occurred at 120mg a day in 6 patients and at 160mg in 10)

From: 19, Cardiac syndrome X

Cover of Stable Angina
Stable Angina: Methods, Evidence & Guidance [Internet].
NICE Clinical Guidelines, No. 126.
National Clinical Guidelines Centre (UK).
Copyright © 2011, National Clinical Guidelines Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of the National Clinical Guidelines Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.